Mobile website
Clinical Research
Expression of ERCC1 in nasopharyngeal carcinoma tissues and its relationship with chemosensitivity to cisplatin
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective ：To examine the expression of ERCC1 (excision repair crosscomplementing 1, ERCC1) in nasopharyngeal carcinoma (NPC) tissues and its relationship with chemosensitivity to cisplatinbased chemotherapy. Methods: Eightytwo patients with advanced NPC, who were diagnosed at Nanxisan hospital of Guangxizhuang autonomous region from June 2006 to June 2008, were treated with cisplatin+5FU regimen. The expression of ERCC1 in 82 nasopharyngeal carcinoma (NPC) tissues and in 34 adjacent normal tissues was detected by immunohistochemistry assay. Results: The positive rate of ERCC1 expression in NPC adjacent normal tissues was significantly higher than that in NPC tissues (88.2% vs 63.4%, P<0.05). Expression of ERCC1 in NPC was positively correlated with patients′ age, but not with gender, T stage, N stage and M stage (P>0.05). The efficacy rate of cisplatinbased chemotherapy in ERCC1 positive NPC patients was significantly higher than that in ERCC1 negative patients (63.3% vs 36.5%, P<0.05). Conclusion: ERCC1 is lowly expressed in advanced NPC tissues; its expression is negatively correlated with the chemosensitivity to cisplatin+5FU regimen. ERCC1 can be used to predict the sensitivity of NPC patients to cisplatinbased chemotherapy.
Keywords:
Project Supported:
Supported by the Scientific Research and Technological Development Program of Guilin, Guangxi Province (No.20070514)
Clc Number:
